TD Waterhouse Canada Inc. Has $2.68 Million Stake in Gilead Sciences, Inc. $GILD

TD Waterhouse Canada Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,813 shares of the biopharmaceutical company’s stock after purchasing an additional 6,583 shares during the quarter. TD Waterhouse Canada Inc.’s holdings in Gilead Sciences were worth $2,677,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter worth approximately $26,000. Financial Consulate Inc. grew its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares in the last quarter. MTM Investment Management LLC grew its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares in the last quarter. BOCHK Asset Management Ltd acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Millstone Evans Group LLC grew its position in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Citigroup increased their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Rothschild & Co Redburn increased their price target on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Leerink Partners increased their price target on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.35.

Gilead Sciences Trading Down 0.3%

NASDAQ GILD opened at $132.90 on Thursday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a market cap of $164.96 billion, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39. The business’s fifty day moving average is $143.30 and its 200 day moving average is $131.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the business posted $1.90 EPS. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 8.63 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares of the company’s stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares in the company, valued at approximately $18,152,687.84. This trade represents a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 294,280 shares of company stock valued at $42,302,950 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead enters earnings season with recent upside: the company beat estimates in its last quarter and carries FY2026 guidance (management’s prior range gives investors a clear target to compare against at the May 7 release). This provides a constructive baseline if management reaffirms or tightens guidance.
• Neutral Sentiment: Gilead announced it will release Q1 2026 results and host a webcast on Thursday, May 7 after the close — a near-term catalyst that will likely drive volatility as investors seek updates on product launches and M&A strategy. Gilead earnings release
• Neutral Sentiment: Market previews note the upcoming report will test the commercial traction of Yeztugo and management’s M&A strategy — these execution items (product launch metrics, pipeline updates, capital deployment plans) will shape near‑term investor sentiment. Investing.com preview
• Negative Sentiment: Zacks Research trimmed Q1–Q4 and FY2026 EPS estimates slightly (FY down to ~$8.29 from ~$8.34), signaling modest analyst downgrades ahead of results — downward revisions can pressure the stock if the company fails to beat the lower bar.
• Negative Sentiment: Regulatory/commercial competition: MSD (Merck) won FDA approval for a once‑daily HIV combo (Idvynso). Analysts expect it could become a strong seller, adding competitive pressure to incumbent HIV franchises and potentially capping pricing/market-share upside. MSD Idvynso approval
• Negative Sentiment: Recent analyst comparisons favor Bristol Myers (BMY) over Gilead on valuation and growth outlook, which can shift investor flows away from GILD in the near term. Bristol Myers vs Gilead

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.